Xueyan Zhang

B. Han, Yu Dong, Xueyan Zhang, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expression Level of Wnt5a Was Related to the Therapeutic Effects of First-Generation EGFR-TKIs

B. Han, Xueyan Zhang, H. Zhong, 2020, OncoTargets and therapy.

EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.

B. Han, Bo Jin, Xueyan Zhang, 2016, Lung cancer.

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China

B. Han, Bo Jin, Xueyan Zhang, 2016, Journal of Cancer Research and Clinical Oncology.

Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)

Bo Zhang, Xueyan Zhang, Huimin Wang, 2022, BMC cancer.

Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?

B. Han, Xueyan Zhang, Huimin Wang, 2018, Lung cancer.

EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

B. Han, Bo Jin, Xueyan Zhang, 2016, Scientific Reports.

Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

B. Han, Bo Jin, Xueyan Zhang, 2016, Scientific Reports.

Reliability of using circulating tumor cells for detecting epidermal growth factor receptor mutation status in advanced non-small-cell lung cancer patients: a meta-analysis and systematic review

Xueyan Zhang, Huimin Wang, P. Gu, 2018, OncoTargets and therapy.

Combination of chemotherapy and gefitinib as first‐line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial

B. Han, Bo Jin, Yu Dong, 2017, International journal of cancer.

MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma

B. Han, Xueyan Zhang, Huimin Wang, 2016, Oncotarget.

Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study

B. Han, Xueyan Zhang, Huimin Wang, 2020, Targeted Oncology.

Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma

Xueyan Zhang, Huimin Wang, W. Nie, 2019, Cancer management and research.

CMAR_A_196881 3433..3443

Xueyan Zhang, Huimin Wang, W. Nie, 2019 .

Clinical Features and Outcomes Analysis of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy

B. Han, Xueyan Zhang, Jianlin Xu, 2020, Frontiers in Oncology.

Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients.

B. Han, Xueyan Zhang, W. Nie, 2019, Lung cancer.

Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non‐small‐cell lung cancer patients with EGFR mutations

B. Han, Bo Jin, Xueyan Zhang, 2017, International journal of cancer.

CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients

B. Han, Xueyan Zhang, Huimin Wang, 2020, Frontiers in Oncology.

OCT4&SOX2‐specific cytotoxic T lymphocytes plus programmed cell death protein 1 inhibitor presented with synergistic effect on killing lung cancer stem‐like cells in vitro and treating drug‐resistant lung cancer mice in vivo

B. Han, Xueyan Zhang, Huimin Wang, 2018, Journal of cellular physiology.

Reevaluation of survival and prognostic factors in pathologic stage I lung adenocarcinoma by the new 2009 TNM classification

Bo Jin, Xueyan Zhang, Huimin Wang, 2014, Tumor Biology.

Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery.

B. Han, Xueyan Zhang, H. Zhong, 2020, Lung cancer.

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update

Hongyu Liu, Xueyan Zhang, Huimin Wang, 2022, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer

B. Han, Bo Jin, Xueyan Zhang, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinicopathological characteristics and gene analysis of pulmonary granular cell tumor in three cases and a systematic review

Xueyan Zhang, Feng Li, Yanwei Zhang, 2020, Translational cancer research.

Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial

Xueyan Zhang, H. Zhong, Jun Lu, 2022, Journal of Cancer Research and Clinical Oncology.

Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment-naïve advanced non-squamous non-small cell lung cancer patients.

Xueyan Zhang, Jiayuan Sun, Junyi Ye, 2018, Lung cancer.

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

B. Han, Xueyan Zhang, H. Zhong, 2021, Respiratory Research.

Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma

B. Han, Xueyan Zhang, Y. Lou, 2019, Targeted Oncology.

Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer

Y. Li, Xueyan Zhang, H. Zhong, 2023, Frontiers in Immunology.